This is what analysts have to say about Summit Therapeutics plc (NASDAQ:SMMT) after last week.

June 13, 2018 - By Winifred Garcia

Summit Therapeutics plc (NASDAQ:SMMT) Logo

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 7 analysts covering Summit Therapeutics (NASDAQ:SMMT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Summit Therapeutics had 9 analyst reports since January 4, 2018 according to SRatingsIntel. Oppenheimer maintained it with “Outperform” rating and $30 target in Friday, January 26 report. The company was maintained on Friday, April 13 by SunTrust. On Tuesday, March 6 the stock rating was maintained by Canaccord Genuity with “Buy”. Canaccord Genuity maintained it with “Buy” rating and $2800 target in Wednesday, April 11 report. Below is a list of Summit Therapeutics plc (NASDAQ:SMMT) latest ratings and price target changes.

02/05/2018 Broker: Janney Capital Rating: Buy New Target: $27 Initiates Coverage On
12/04/2018 Broker: Needham Rating: Buy New Target: $27.0000
13/04/2018 Broker: SunTrust Rating: Buy New Target: $22.0000 Maintain
11/04/2018 Broker: Canaccord Genuity Rating: Buy New Target: $28.0000 Maintain
28/03/2018 Broker: JMP Securities Rating: Buy New Target: $42.0000
06/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $28.0 Maintain
13/02/2018 Broker: BTIG Research Rating: Buy New Target: $33 Initiates Coverage On
26/01/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Outperform Old Target: $24 New Target: $30 Maintain
04/01/2018 Broker: SunTrust Rating: Buy New Target: $24 Initiates Coverage On

The stock decreased 0.23% or $0.03 during the last trading session, reaching $12.8. About 5,585 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 11.61% since June 13, 2017 and is uptrending. It has underperformed by 0.96% the S&P500.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $208.65 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More notable recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: Globenewswire.com which released: “Summit Therapeutics plc : 1st Quarter Results” on June 05, 2018, also Globenewswire.com with their article: “Summit Therapeutics Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018” published on June 11, 2018, Nasdaq.com published: “Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018” on June 11, 2018. More interesting news about Summit Therapeutics plc (NASDAQ:SMMT) were released by: Nasdaq.com and their article: “Consolidated Research: 2018 Summary Expectations for Summit Therapeutics, Orbotech, Amphastar Pharmaceuticals …” published on June 05, 2018 as well as Nasdaq.com‘s news article titled: “Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress” with publication date: June 05, 2018.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: